Booster influenza vaccination has been recommended for patients with chronic renal disease in order to enhance the immune response to the influenza vaccine; however, the efficacy of a booster influenza vaccination is a matter of controversy. Therefore, we made a meta-analysis to determine the efficacy in patients with hemodialysis (HD), peritoneal dialysis (PD) and renal transplant recipient (RT). The sero-protection rate was used as a serologic parameter to describe the immune response to the vaccine. Statistical analysis was performed to calculate the pooled rate difference (RD) and 95% confidence interval (CI). The pooled RD for the H1N1, H3N2 and B influenza vaccines was 0.02 (95% CI: ¡0.02-0.06), 0.05 (95% CI: ¡0.01-0.11), 0.04 (95% CI: ¡0.02-0.10), respectively. We concluded that a booster dose of the influenza vaccine did not effectively enhance immunogenicity. Therefore, a booster dose of vaccine is not recommended for patients with hemodialysis, peritoneal dialysis and renal transplant recipients.
REVIEW
Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: A systematic literature review and meta-analysis 
Introduction
Influenza leads to a substantial increase in morbidity and mor-20 tality each year. Worldwide, influenza infection causes 3-5 -million severe illnesses and 250,000-500,000 deaths annually. 1 Patients with chronic renal disease have a higher mortality rate than the general population. Compared with the general population, the annual mortality rate for sepsis is 20-fold higher in 25 transplant recipients and 100 to 300-fold higher in dialysis patients. 2 Because chronic renal disease patients have compromised immunity, they are vulnerable to influenza infection. 3, 4 Moreover, influenza infection results in severe complications. Influenza infection is a significant threat to this population of 30 patients. For the above reasons, these patients benefit from prevention of influenza infection more so than the general population.
In healthy people the influenza vaccination is safe and effective, but challenges exist when the influenza vaccine is 35 administered to patients with chronic renal disease. Indeed, it has been reported that the influenza vaccine has weakened efficacy in patients with chronic renal disease. 5 Under such circumstances, many strategies have been proposed to strengthen the immunogenicity of the influenza vaccine; a 40 booster vaccination is one compelling example. Although this measure was implemented in 1987 by Versluis et al., 6 the anticipated effect has not been clearly established in these patients. The booster vaccination means increasing the influenza antigen supply to patients with chronic renal disease,
45
which would accelerate depletion of the limited global influenza antigen supply. The benefit of a booster vaccination has been a matter of controversy in patients with HD, PD and RT. Only a few studies have addressed this issue, and the reliability of the studies 50 was limited because of the small number of patients. A metaanalysis is thus a useful tool to collate the scattered evidence.
In the current study we determined the efficacy of a booster influenza vaccination in patients with chronic renal disease, including patients undergoing hemodialysis, peritoneal dialysis, 55 and kidney transplantation, and verified the clinical benefit of a booster influenza vaccination.
Results

Literature review
Three hundred 3 relevant records were retrieved from the 60 China National Knowledge Infrastructure (CNKI), Pubmed, Cochrane Library, Embase, and ScienceDirect databases. Only nine full text articles were eligible after screening. All of the studies were cohort studies. The quality of all studies was >5 stars. The details of the process are shown in Figure 1 .
70 abstracted information from one study that had the most detailed data to avoid pooling the data from overlapping populations.
Description of included studies
The eligible publications included 2 from The Netherlands, 2 75 from Belgium, and one each from Italy, Korea, Spain, Germany, and France (Table 1 ). All of the papers were published between 1987 and 2013. Most of the patients who were recruited in the studies were elderly. The exact number of patients could not be derived from the original studies. In only one study was a com-80 parison (first vs. booster vaccination) made between different groups of patients.
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The vaccine used in all the studies was monovalent or trivalent, and administered via the intramuscular route Note: HD, hemodialysis; HD_C, control group who was hemodialysis patient receiving one dose of vaccine; PD, peritoneal dialysis; RT, renal transplant; F/M, female/male; NA, not available; NOS, the Newcastle-Ottawa Scale for cohort studies; S N , the number of stars for cohort selection section; C N , the number of stars for cohort comparability section; O N , the number of stars for cohort outcome section; T N , the total number of stars.
( Table 2 ). The formation of influenza vaccine was subunit 85 and split. MF-59 and AS03A adjuvant was applied in 3 studies. 8, 12, 13 The interval between the first and booster vaccination ranged from 28-90 d. The interval between vaccination and serology was 21-30 d. The dosage of influenza vaccine in 8 eligible studies was 15 mg for each virus strain. 90 In the other 2 studies, the dosage of H1N1 vaccine was 3.75 mg.
Risk of bias assessment
Several aspects of the study might have caused bias. Booster vaccination might have a distinct influence on patients with 95 different renal conditions. The interval between the first and booster vaccination was different in the eligible studies. Different schedules for booster vaccination may have diverse efficacy. Different formations of the vaccine could produce inconsistent immunogenicity. Age is also a significant factor 100 which affects the immunogenicity of a vaccine. The age of the patients was heterogeneous in different groups. Years on dialysis might have an effect on the immune system. The patients with different years on dialysis might have various humoral responses to the influenza vaccine. Because of possi-105 ble risk of bias from above sources, subgroup analysis for H1N1 vaccine was performed to determine them. Subgroup analysis showed they did not induce bias (data shown in Table 3 ). The efficacy of the booster vaccination could not influence 110 publication because negative and positive results have equal research value. After analysis, all the evidence from funnel plots and the Egger's test showed that there was no publication bias in the meta-analysis (data not shown).
Efficacy of booster vaccination in patients with HD, PD
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and RT Eight hundred eighty-four patients in the current study had detailed information about the immunogenicity of the first dose of the influenza vaccine. For each virus strain of influenza vaccine, a serologic response of approximately 72% of the 120 patients reached sero-protection (HI antibody titer >40). The sero-protection rates in the patients met the Committee for Proprietary Medical Products (CPMP) criteria. 14 The rate difference (RD) for sero-protection (first vs. booster vaccination) was used to measure the efficacy of an additional 125 dose of the influenza vaccine. The pooled results showed (Fig. 2) that the booster vaccination could not significantly increase the sero-protection rate in patients with HD, PD and RT. The pooled RD for the H1N1 vaccine was 0.02 (95% confidence interval (CI): ¡0.02-0.06). For the H3N2 vaccine, the pooled RD was 130 0.05 (95% CI: ¡0.01-0.11). For the B-type influenza vaccine, the pooled RD was 0.04 (95% CI: ¡0.02-0.10).
In order to better understand the efficacy of booster vaccination in dialysis patients and renal allograft recipients, foldincrease in geometric mean titer (GMT) from pre-booster to 
Discussion
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Our findings showed that a single dose of influenza vaccine induces a sub-optimal immune response, and the effect reaches the CPMP criteria. Thus, a single dose of influenza vaccine is capable of protecting patients with HD, PD and RT from influenza infection. After a booster dose of influenza vaccine was 145 administered to patients, the sero-protection rates increased; however, a booster vaccination did not yield a satisfactory immunopotentiating effect An influenza vaccine is the most cost-effective way to prevent influenza infection. An influenza vaccination can also sig-150 nificantly decrease the number of severe complications and morality rate. It has been reported that influenza vaccine activity is 70%-90% in healthy populations >65 y of age. 15 Our outcomes showed that influenza vaccine activity was slightly reduced in patients with HD, PD and RT. Therefore, the benefi-155 cial effect of influenza vaccine would also be realized in patients with HD, PD and RT. Booster vaccination has long been recommended to patients with a compromised immune system to improve the level of protection of patients with chronic renal disease; however, our 160 results showed that a booster dose of vaccine was not effective.
This finding does not mean that there is no benefit of booster vaccination in other populations. As Gueller et al. reported, 16 after hematopoietic stem cell transplantation, patients benefit from a booster influenza vaccination. The potentiating effect of 165 a booster dose influenza vaccine was also reported in liver transplant recipients. 17 Additional studies are needed to determine the efficacy of booster vaccination in other populations, such as the very elderly, HIV patients, and patients with autoimmune disease.
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The sero-protection rate, mean fold increase in HI antibody titer, and sero-conversion rate are generally used to describe the antibody response to an influenza vaccine. We chose the sero-protection rate as the serologic parameter to measure the immunogenicity of the influenza vaccine 175 because of the public health objectives. HI titer of 40 is generally accepted to represent a 50% protective titer for seasonal influenza A viruses in adult populations. The seroconversion rate and mean fold increase in HI antibody are only related to the immunologic response and cannot assess 180 the economic effectiveness in a population.
An annual influenza vaccine has been recommended, thus a portion of patients with HD, PD and RT had pre-vaccination antibody to the vaccine antigen. In this study we could not assess the influence of pre-vaccination because of lacking ade- booster vaccination; however, the situation that a part of the patients had pre-vaccination was close to an actual real-life situation. One research by Agnieszka Mastalerz-Migas et al. may 190 help us to eliminate above concern.
18 They concluded that although influenza vaccination in previous seasons leads to higher baseline HI titer, it is of little influence on immunoresponse to current influenza immunization in the dialysis patients.
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On the basis of our findings, we believe it is not prudent to recommend a booster influenza vaccination in patients with chronic renal disease. A booster dose of influenza vaccine would result in wasting the limited antibody supply. Our findings would reduce an excess dose of influenza vaccine being 200 offered to patients. Although patients with chronic renal disease have impaired immune response to the influenza vaccine, one dose of influenza vaccine is protective. This phenomenon should attract us to further consider whether or not other efforts on improving the immunogenicity of influenza vaccine 205 in patients are cost-effective.
The present meta-analysis had several limitations. Firstly, sero-protection rate did not completely demonstrate the actual effectiveness of booster vaccination. It is a great challenge to directly assess the actual effectiveness because lacking related 210 studies. Sero-protection rate is an indirect parameter to show the actual effectiveness of vaccine, for at least 50% of vaccinees are protected when the HI titer is >40. Second, Subgroup analysis was performed only on the H1N1 vaccine. Without enough information about the other strain vaccine in the 215 included studies, the present data was difficult to be divided into subgroups.
Conclusion
Although the influenza vaccine had impaired immunogenicity, one dose of influenza vaccine induced an adequate immune 220 response in the patients. A booster dose of the influenza vaccine did not effectively enhance immunogenicity. Therefore, a booster dose of vaccine is not recommended for in patients with hemodialysis, peritoneal dialysis and renal transplant recipients.
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Methods
Retrieval strategy and selection criteria
We searched PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure, and Science Direct databases for articles published before January 2016. The key 230 words used in the retrieval process were influenza vaccine, influenza vaccination, dialysis, hemodialysis, continuous ambulatory peritoneal dialysis, CAPD, peritoneal dialysis, renal failure, chronic renal failure, chronic kidney disease, chronic renal insufficiency, end stage renal disease, ESRD, and CKD. The 235 articles were independently screened by 2 reviewers (YPL and XJX) in the sequence of title, abstract, and full text. Disagreements were resolved by discussion until consensus was achieved. An eligible study must have met the inclusion criteria, as follows: studies involving patients with chronic renal diseases 240 who received an influenza vaccination; the study outcome was hemagglutination-inhibiting (HI) antibody against influenza virus; a comparison of the immunogenicity of the influenza vaccine was made between the standard and booster vaccination in the same or a different group of patients. The exclusion 245 criteria were as follows: study sample size <5; not clear and original data; and duplicated data.
Data abstraction and quality assessment
We discussed which data we needed from each article and designed a questionnaire to survey the articles. The extracted 250 information included the following: authors' names; publication year; study design; sample size; age of patients; years on 
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HUMAN VACCINES AND IMMUNOTHERAPEUTICSdialysis; and vaccine type. The outcome that we abstracted from the articles was the sero-protection rate. The sero-protection rate is a percentage of vaccine recipients with a 255 serum HI titer >1:40 after vaccination. A HI titer >1:40 can be viewed as protective in healthy adults. 19 Study quality was assessed using the Newcastle-Ottawa Scale. 20 The full NOS score was 9 stars which consist of 3 stars from section of cohort selection, 4 stars from section of comparability, and 3 260 stars from section of outcome. At least 2 researchers (XJX, YPL, and ZFL) independently finished extraction and quality assessment after reviewing each article. If there were discrepancies during the abstraction and assessment process between the reviewers, the discrepancies were resolved by 265 discussion.
Data analysis
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Metaanalysis statement. 21 We pooled the outcomes using the Man-270 tel-Haenszel fixed or random model. 22 Selection of the fixedor random-effects model depended on the result of the Cochrane's Q test. Heterogeneity was significant when the p value of the Cochrane's Q test was >10%. 23 When the heterogeneity was significant, the Mantel-Haenszel random model 275 was used. If not, we preferred the Mantel-Haenszel fixed model. The I 2 value indicated the degree of inconsistency among the studies, as follows 24 : <25%, homogeneity; 25%-50%, moderate heterogeneity; 50%-75%, large heterogeneity; and >75%, extreme heterogeneity. 25 Publication bias was 280 assessed through visual inspection of funnel plot asymmetry.
Asymmetry was also tested by Egger's linear regression analysis. 26 Statistical analysis was performed using RevMan version 5.2 (provided by the Cochrane Collaboration) and STATA 13 (StataCorp, College Station, TX, USA). 285 
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